Evaluating PET imaging for neuroendocrine tumors
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.
This study is testing if advanced PET imaging techniques can help doctors better diagnose and monitor neuroendocrine tumors in adult patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS San Raffaele Academic / other |
| Locations | 1 site (Milano, Italia) |
| Trial ID | NCT06159920 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the diagnostic and prognostic capabilities of advanced PET imaging techniques, specifically PET/CT and PET/MRI, in patients with neuroendocrine tumors (NETs). By utilizing innovative radiopharmaceuticals that target somatostatin receptors, the study aims to enhance the accuracy of diagnosing and characterizing these tumors. The research will analyze clinical data and PET imaging results from adult patients who have undergone PET studies for their condition. The goal is to improve the staging and restaging processes for neuroendocrine tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with neuroendocrine tumors who have previously undergone PET imaging.
Not a fit: Patients under 18 years old or those without available clinical data and PET imaging will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better management strategies for patients with neuroendocrine tumors.
How similar studies have performed: Other studies have shown promising results with similar PET imaging approaches in oncology, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients affected by neuroendocrine tumors; Patients who have performed at least one PET study with 18F-FDG and/or 68Ga- DOTATOC for the staging or diagnosis of their pathology. Exclusion Criteria: * Patients \< 18 years old; * Lack of availability of clinical data and PET imaging useful for analyses.
Where this trial is running
Milano, Italia
- Irccs San Raffaele — Milano, Italia, Italy (Recruiting)
Study contacts
- Study coordinator: Arturo Chiti
- Email: chiti.arturo@hsr.it
- Phone: 0226432716
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.